Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that CEO Arthur T. Sands will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 3:40 PM ET. The event will be webcast live and accessible via the Investors section of the Nurix website. This clinical-stage biopharmaceutical company focuses on developing small molecule therapies targeting E3 ligases to treat cancer and other diseases, utilizing its proprietary DELigase platform.
- None.
- None.
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 3:40 PM ET.
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurixtx.com.
Contacts:
| Investors: | Media: |
| Elizabeth Wolffe, Ph.D. | Brett Whelan |
| Wheelhouse Life Science Advisors | LifeSci Communications |
| lwolffe@wheelhouselsa.com | bwhelan@lifescicomms.com |
FAQ
When will Arthur T. Sands speak at the SVB Leerink Global Healthcare Conference?
How can I access the webcast of the Nurix Therapeutics event?
What does Nurix Therapeutics focus on?
